Lab
Chrome Residential, LLC
Chrome Residential, LLC was paid $1.21M by Medicaid between Feb 2022 and Nov 2023, across 11 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 36% of everything it billed.
33Billing provider infoCHROME RESIDENTIAL, LLC
SHERMAN OAKS, CA 91423
SHERMAN OAKS, CA 91423
33aNPI1346989704assigned 06/02/2022
33bProvider typeClinical Medical Laboratory
28Total paid$1.21M
24GClaims35,784
24DCodes billed11
24AFirst – last monthFeb 2022 – Nov 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#181 of 561
Median peer was paid$222K
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 25,922 | $915K | |
| 2023 | 9,862 | $299K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 36% | 6,669 | 1,884 | $435K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 28% | 7,129 | 1,950 | $339K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 12% | 7,159 | 2,064 | $150K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5.9% | 3,240 | 978 | $72K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 5.1% | 1,610 | 587 | $62K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5.0% | 1,931 | 601 | $61K |
| 86409 | 4.0% | 659 | 658 | $48K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 213 | 122 | $16K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.3% | 345 | 228 | $16K |
| 87400 | 1.1% | 5,446 | 908 | $13K | |
| 82784 | <1% | 1,383 | 287 | $3K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBENCHLOUCH HARAR, JACOB (OWNER)